SOLGENT
SOLGENT
DiaPlexQ™ Apolipoprotein E (ApoE) Genotyping Kit (Alzheimer's Disease)
Model
Series
Molecular Diagnostic (Human Gentrifyping)
Transaction Process
Please contact the manufacturer/supplier.
Payment
Contact the manufacturer/supplier.
Delivery
Contact the manufacturer/supplier.
Shipment
Contact the manufacturer/supplier.
Origin
Contact the manufacturer/supplier.
Description
DiaPlexQ™Apolipoprotein E (ApoE) Genotyping Kit
Real-Time PCR based assay system for the genotyping of the ApoE gene SNP related to alzheimer’s disease
CE-IVD
Apolipoprotein E (ApoE) consists of three isoforms: E2, E3 and E4. These three isoforms make six genotypes, (homozygous genotypes: E2/E2, E3/E3 E4/E4 and heterozygous genotypes: E2/E3, E2/E4, E3/E4). Isoform E2 is usually known as a protective isoform whereas isoform E4 is generally responsible for diseases. The predominant abnormalities are due to a single nucleotide polymorphism (SNP) of codon 112 (Cys/Arg) and codon 158 (Arg/Cys). The polymorphism has functional effects on the lipoprotein metabolism. ApoE is the primary ligand for two receptors, LDL receptors found in the liver and other tissues and ApoE specific receptors found in the liver. The co-ordinate interaction of these lipoprotein complexes with their receptors forms the basis for the metabolic regulation of cholesterol. ApoE has been found to be associated with elevated cholesterol levels or lipid derangements that lead to various clinical problems like coronary heart diseases, strokes, periphery artery diseases, and diabetes mellitus. In addition to the genotype-phenotype associations with the cardiovascular disease, the alleles and isoforms of ApoE have been related to dementias, most commonly Alzheimer’s disease. Determining the genotype of ApoE is thus considered to be an important test for patients with the disease, as well as a precautionary test for healthy people.
Specification
| DiaPlexQ™ ApoE Genotyping Kit | ||
|---|---|---|
| Detection target | ApoE genotype (Mutation T112C and T158C of ApoE gene) E2/E2, E3/E3, E4/E4, E2/E3, E2/E4, E3/E4 | |
| Registration | CE-IVD | |
| Detection technology | Real-Time PCR | |
| Specimen type | Blood | |
| Compatible instruments* | ABI 7500 / 7500 Fast Real-Time PCR System (Applied Biosystems) CFX96™ Real-Time PCR System (Bio-Rad) | |
| PCR running time | ~ 1 hr 30 min | |
Features
- HotStart PCR system : Ultra high specific and sensitive result
- UDG system : No carryover contamination ( DiaPlexQ™)
- Multiplex PCR : Multiple targets in a single reaction
- Reliable system : Automatic Internal control ( DiaPlexC™)
- Positive control included
- Easy-to-use master mix
- CE certification
Experimental
| ApoE genotype | SNP | 112 site | 158 site |
|---|---|---|---|
| E2/E2 | TT/TT | ● T/T type | ● T/T type |
| E2/E3 | TT/TC | ● T/T type | ● T/C type |
| E2/E4 | TC/TC | ● T/C type | ● T/C type |
| E3/E3 | TT/CC | ● T/T type | ● C/C type E4 |
| E3/E4 | TC/CC | ●T/C type | ● C/C type E4 |
| E4/E4 | CC/CC | ● C/C type E4 | ● C/C type E4 |
| ● Non-Template Control | |||
Citation&Papers
Lepara O, Valjevac A, Alajbegovic A, Zaciragic A, Nakas-Icindic E (August 2009). Decreased serum lipids in patients with probable Alzheimer’s disease”. Bosn J Basic Med Sci 9 (3): 215-20. | Golomb BA, Evans MA (2008). “Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism”. Am J Cardiovasc Drugs 8 (6): 373-418 |
Ordering information
| Technology | Cat. No. | Product | Contents |
|---|---|---|---|
Real-Time PCR | SQH01-K020 (20 reaction) | DiaPlexQ ™ ApoE Genotyping Kit | 2X Multiplex Real-Time PCR Smart mix (ApoE) Primer & Probe Mixture (ApoE 112) Primer & Probe Mixture (ApoE 158) T/T type Control DNA (ApoE 112) T/C type Control DNA (ApoE 112) C/C type Control DNA (ApoE 112) T/T type Control DNA (ApoE 158) T/C type Control DNA (ApoE 158) C/C type Control DNA (ApoE 158) Nuclease free Water |
SQH01-K100 (100 reaction) |